| Drug Name |
Cobicistat |
| Drug ID |
BADD_D00512 |
| Description |
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. |
| Indications and Usage |
Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. |
| Marketing Status |
approved |
| ATC Code |
V03AX03 |
| DrugBank ID |
DB09065
|
| KEGG ID |
D09881
|
| MeSH ID |
D000069547
|
| PubChem ID |
25151504
|
| TTD Drug ID |
D02VJP
|
| NDC Product Code |
63285-889; 66721-500; 54014-9350; 57572-0035; 61958-1401 |
| UNII |
LW2E03M5PG
|
| Synonyms |
Cobicistat | Tybost | GS 9350 | 9350, GS | GS9350 | GS-9350 |
